Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer
Top Cited Papers
- 10 May 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (14) , 1296-1308
Abstract
PURPOSE: To examine the associations between Medicaid expansion and stage at diagnosis, timely initiation and receipt of guideline-concordant treatment, and 5-year overall survival (OS) among people with non–small cell lung cancer (NSCLC). METHODS: Individuals newly diagnosed with stage I to IV NSCLC at age 18-64 years between January 1, 2004, and December 31, 2023, in 50 states and Washington, DC, were identified from the National Cancer Database. We examined the association of Medicaid expansion and (1) early-stage diagnosis (I and II); (2) timely initiation of guideline-concordant treatment within 30 days after diagnosis; (3) receipt of all first-course guideline-concordant treatment; and (4) 5-year OS. We applied conventional and updated (Sun and Abraham) difference-in-differences (DID) approaches to examine the changes in study outcomes associated with Medicaid expansion using multivariable linear probability models to estimate stage and treatment and multivariable flexible parametric survival models to investigate survival overall and by key factors. RESULTS: Compared with people in nonexpansion states (n = 164,228), people in expansion states (n = 350,290) were more likely to be female, non-Hispanic White, or living in areas with higher family income or in nonmetropolitan areas. Medicaid expansion was associated with increases in early-stage NSCLC diagnosis (DID: 1.02 percentage points [ppt; 95% CI, 0.52 to 1.52]), timely treatment initiation (2.10 ppt [95% CI, 0.05 to 4.15]), and higher 5-year OS (1.79 ppt [95% CI, 1.32 to 2.26]). In stratified analyses, people living in areas with lower household income were more likely to benefit from Medicaid expansion. CONCLUSION: Medicaid expansion was associated with improvements in early detection, timeliness of guideline-concordant treatment, and survival for people with NSCLC. Anticipated Medicaid coverage losses may jeopardize these gains.Keywords
This publication has 41 references indexed in Scilit:
- COVID-19 and Rates of Cancer Diagnosis in the USJAMA Network Open, 2024
- Medicaid Expansion Under the Affordable Care Act and Early Mortality Following Lung Cancer SurgeryJAMA Network Open, 2024
- Association of Medicaid expansion with 2‐year survival and time to treatment initiation in gastrointestinal cancer patients: A National Cancer Database studyJournal of Surgical Oncology, 2023
- Overall lung cancer screening rates lowCancer, 2023
- Association of Medicaid expansion with racial disparities in cancer stage at presentationCancer, 2022
- Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common CancersJAMA Network Open, 2020
- Association of Medicaid Expansion Under the Patient Protection and Affordable Care Act With Non–Small Cell Lung Cancer SurvivalJAMA Oncology, 2020
- Association of Medicaid Expansion Under the Affordable Care Act With Insurance Status, Cancer Stage, and Timely Treatment Among Patients With Breast, Colon, and Lung CancerJAMA Network Open, 2020
- Comparison of Insurance Status and Diagnosis Stage Among Patients With Newly Diagnosed Cancer Before vs After Implementation of the Patient Protection and Affordable Care ActJAMA Oncology, 2018
- Increasing time to treatment initiation for head and neck cancer: An analysis of the National Cancer DatabaseCancer, 2014